Patents by Inventor Eric HUMKE

Eric HUMKE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF HUMAN EPIDIDYMIS PROTEIN 4 (HE4) FOR ASSESSING RESPONSIVENESS OF MUC 16-POSITIVE CANCER TREATMENT
    Publication number: 20230064677
    Abstract: The present invention relates to methods and kits or articles of manufacture related thereto that may find use, inter alia, in assessing responsiveness of cancers to MUC16 antagonists by monitoring HE4 expression. In some embodiments, the methods include measuring the level of expression of HE4 in a sample from a subject; comparing the level of expression of HE4 in the sample with the level of expression of HE4 in a sample previously obtained from the subject; and, optionally, administering to the subject a therapeutically effective amount of a MUC16 antagonist.
    Type: Application
    Filed: August 2, 2022
    Publication date: March 2, 2023
    Applicant: Genentech, Inc
    Inventors: Mark LACKNER, Daniel Maslyar, Yulei Wang, Walter Darbonne, Eric Humke
  • Use of human epididymis protein 4 (HE4) for assessing responsiveness of MUC 16-positive cancer treatment
    Patent number: 11440969
    Abstract: The present invention relates to methods and kits or articles of manufacture related thereto that may find use, inter alia, in assessing responsiveness of cancers to MUC16 antagonists by monitoring HE4 expression. In some embodiments, the methods include measuring the level of expression of HE4 in a sample from a subject; comparing the level of expression of HE4 in the sample with the level of expression of HE4 in a sample previously obtained from the subject; and, optionally, administering to the subject a therapeutically effective amount of a MUC16 antagonist.
    Type: Grant
    Filed: January 4, 2019
    Date of Patent: September 13, 2022
    Assignee: Genentech, Inc.
    Inventors: Mark Lackner, Daniel Maslyar, Yulei Wang, Walter Darbonne, Eric Humke
  • USE OF HUMAN EPIDIDYMIS PROTEIN 4 (HE4) FOR ASSESSING RESPONSIVENESS OF MUC 16-POSITIVE CANCER TREATMENT
    Publication number: 20190233538
    Abstract: The present invention relates to methods and kits or articles of manufacture related thereto that may find use, inter alia, in assessing responsiveness of cancers to MUC16 antagonists by monitoring HE4 expression. In some embodiments, the methods include measuring the level of expression of HE4 in a sample from a subject; comparing the level of expression of HE4 in the sample with the level of expression of HE4 in a sample previously obtained from the subject; and, optionally, administering to the subject a therapeutically effective amount of a MUC16 antagonist.
    Type: Application
    Filed: January 4, 2019
    Publication date: August 1, 2019
    Applicant: Genentech, Inc.
    Inventors: Mark LACKNER, Daniel MASLYAR, Yulei WANG, Walter DARBONNE, Eric HUMKE